Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.

Tronieri JS, Wadden TA, Walsh OA, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Chao AM

Metabolism: clinical and experimental20 Mar 2019Cited by 14 (Europe PMC)

PMID30902750PMCIDPMC6571049DOI10.1016/j.metabol.2019.03.005PepBankPUB-30902750

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, those who continued liraglutide 3.0 mg plus placebo lost a mean of 0.1% of re-randomization weight over 12 weeks.
In plain wordsIn adults with obesity who had lost weight on liraglutide, those who stayed on liraglutide plus placebo lost almost no further weight in 12 weeks.
Peptide
Liraglutide
Outcome
Direction not reportedWeight change at week 12 on liraglutide plus placebo
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 12 weeksAs given in this study (human).
Measurements
Weight loss
0.1%
liraglutide-placebo, week 12
Source sentences
Summary
At week 12, the liraglutide-phentermine and liraglutide-placebo groups lost a mean (±SEM) of 1.6 ± 0.6% and 0.1 ± 0.5% of re-randomization weight, respectively (p = 0.073).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
Report a problemFND-3090275005
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, one participant (4.3%) continuing liraglutide plus placebo lost at least 5% of re-randomization weight.
In plain wordsIn adults with obesity who had lost weight on liraglutide, one person (4.3%) who stayed on liraglutide plus placebo lost a further 5% or more.
Peptide
Liraglutide
Outcome
Direction not reportedParticipant losing at least 5% of weight on liraglutide plus placebo
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 12 weeksAs given in this study (human).
Measurements
Participants losing >=5% weight
1 participants
liraglutide-placebo
Proportion losing >=5% weight
4.3%
liraglutide-placebo
Source sentences
Summary
Two (9.1%) liraglutide-phentermine participants and one (4.3%) liraglutide-placebo participant lost ≥5% of re-randomization weight; 19 (86.4%) and 16 (69.9%) participants, respectively, maintained their full weight loss achieved in the prior 1-year trial (p = 0.125).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
Report a problemFND-3090275006
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, 16 participants (69.9%) continuing liraglutide plus placebo maintained their full prior weight loss.
In plain wordsIn adults with obesity who had lost weight on liraglutide, 16 people (69.9%) who stayed on liraglutide plus placebo kept off their full weight loss.
Peptide
Liraglutide
Outcome
Direction not reportedParticipants maintaining full prior weight loss on liraglutide plus placebo
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 12 weeksAs given in this study (human).
Measurements
Participants maintaining full weight loss
16 participants
liraglutide-placebo
Proportion maintaining full weight loss
69.9%
liraglutide-placebo
Source sentences
Summary
Two (9.1%) liraglutide-phentermine participants and one (4.3%) liraglutide-placebo participant lost ≥5% of re-randomization weight; 19 (86.4%) and 16 (69.9%) participants, respectively, maintained their full weight loss achieved in the prior 1-year trial (p = 0.125).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
Report a problemFND-3090275007

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, adding phentermine to liraglutide gave a weight loss of 1.6% at week 12 versus 0.1% with liraglutide plus placebo; the difference was not significant.
In plain wordsIn adults with obesity who had lost weight on liraglutide, adding phentermine did not significantly change weight compared with liraglutide plus placebo.
Peptide
Liraglutide
Outcome
No significant changeWeight change at week 12
Study
n = 45
Comparator
Liraglutide plus placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
1.6%
liraglutide-phentermine, week 12
Weight loss
0.1%
liraglutide-placebo, week 12
Source sentences
Summary
At week 12, the liraglutide-phentermine and liraglutide-placebo groups lost a mean (±SEM) of 1.6 ± 0.6% and 0.1 ± 0.5% of re-randomization weight, respectively (p = 0.073).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3090275001
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, 2 participants taking liraglutide plus phentermine and 1 taking liraglutide plus placebo lost at least 5% of their weight.
In plain wordsIn adults with obesity who had lost weight on liraglutide, 2 people with added phentermine and 1 with placebo lost a further 5% or more.
Peptide
Liraglutide
Outcome
Direction not reportedParticipants losing at least 5% of weight
Study
n = 45
Comparator
Liraglutide plus placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Participants losing >=5% weight
2 participants
liraglutide-phentermine
Participants losing >=5% weight
1 participants
liraglutide-placebo
Source sentences
Summary
Two (9.1%) liraglutide-phentermine participants and one (4.3%) liraglutide-placebo participant lost ≥5% of re-randomization weight; 19 (86.4%) and 16 (69.9%) participants, respectively, maintained their full weight loss achieved in the prior 1-year trial (p = 0.125).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3090275002
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, the number who kept their full weight loss did not differ significantly between liraglutide plus phentermine and liraglutide plus placebo.
In plain wordsIn adults with obesity who had lost weight on liraglutide, adding phentermine did not significantly change how many kept off their full weight loss.
Peptide
Liraglutide
Outcome
No significant changeParticipants maintaining full prior weight loss
Study
n = 45
Comparator
Liraglutide plus placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Participants maintaining full weight loss
19 participants
liraglutide-phentermine
Participants maintaining full weight loss
16 participants
liraglutide-placebo
Source sentences
Summary
Two (9.1%) liraglutide-phentermine participants and one (4.3%) liraglutide-placebo participant lost ≥5% of re-randomization weight; 19 (86.4%) and 16 (69.9%) participants, respectively, maintained their full weight loss achieved in the prior 1-year trial (p = 0.125).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3090275003
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity who had lost weight on liraglutide, liraglutide plus phentermine participants reported larger reductions in hunger and food preoccupation than liraglutide plus placebo participants in the first 8 weeks.
In plain wordsIn adults with obesity who had lost weight on liraglutide, people taking added phentermine reported larger drops in hunger than those taking placebo.
Peptide
Liraglutide
Outcome
DecreaseHunger and food preoccupation
Study
n = 45
Comparator
Liraglutide plus placebo
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Liraglutide-phentermine participants generally reported larger reductions in hunger and food preoccupation than liraglutide-placebo participants during the first 8 weeks of the extension study.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were 45 adults with obesity (75.6% female, 55.6% white, body mass index = 34.3 ± 4.7 kg/m²) who had lost an average of 12.6 ± 6.8% of initial weight during a prior 1-year randomized trial with liraglutide and intensive behavioral treatment.
Summary · context
Participants were re-randomized, in a double-blinded fashion, to liraglutide 3.0 mg plus phentermine 15.0 mg (liraglutide-phentermine) or liraglutide plus placebo (liraglutide-placebo).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3090275004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02911818

Lifestyle Modification and Liraglutide

University of Pennsylvanian = 150Sept 2016 to Dec 2018

Obesity

Trial page ClinicalTrials.govUpdated 7 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.